Scarica l'app Stockscreener
13.78
1.64%
-0.23
Dopo l'orario di chiusura:
13.82
0.04
+0.29%
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
William Blair Analysts Increase Earnings Estimates for SPRY - MarketBeat
What is Leerink Partnrs' Forecast for SPRY FY2024 Earnings? - MarketBeat
Emily Leonard - Global Legal Chronicle
Oliver Hodgkiss - Global Legal Chronicle
ALK’s Licensing Agreement with ARS Pharmaceuticals - Global Legal Chronicle
Royce & Associates LP Purchases 45,755 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
(SPRY) On The My Stocks Page - Stock Traders Daily
What is Leerink Partnrs' Estimate for SPRY FY2027 Earnings? - MarketBeat
Q4 EPS Estimate for ARS Pharmaceuticals Boosted by Analyst - MarketBeat
Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term - Yahoo Finance
NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES - PR Newswire
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q3 2024 Earnings Call Transcript - Insider Monkey
GSA Capital Partners LLP Boosts Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals earnings missed by $0.06, revenue topped estimates - Investing.com Canada
ARS Pharmaceuticals’ Strong Q3 2024 Highlights - TipRanks
Deerfield management sells ARS Pharmaceuticals shares for $10.14 million - Investing.com India
Deerfield management sells ARS Pharmaceuticals shares for $10.14 million By Investing.com - Investing.com Canada
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
ARS Pharma Launches Groundbreaking Needle-Free Epinephrine Spray, Secures $465M Deal | SPRY Stock News - StockTitan
Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings - Benzinga
ARS Pharmaceuticals inks global deal for epinephrine product By Investing.com - Investing.com Canada
ARS Pharmaceuticals inks global deal for epinephrine product - Investing.com
ARS Pharmaceuticals announces agreement with ALK to commercialize neffy - Yahoo Finance
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray - Yahoo! Voices
ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m - Yahoo Finance
ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week HighTime to Buy? - MarketBeat
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 - Yahoo Finance
ARS Pharmaceuticals Announces Exclusive Agreement with - GlobeNewswire
ARS Pharma Lands $465M Global Deal for Needle-Free Allergy Drug neffy® | SPRY Stock News - StockTitan
Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet - MSN
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) - The Manila Times
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
ARS Pharmaceuticals (SPRY) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Institutional investors control 35% of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) and were rewarded last week after stock increased 10% - Simply Wall St
The Physician-Patient Alliance for Health & Safety Expands Board of Advisors with Five Healthcare Industry Leaders, Enhancing Commitment to Patient Safety and Innovation - GlobeNewswire Inc.
ARS Pharmaceuticals Announces Conference Call and Webcasts - GlobeNewswire
ARS Pharmaceuticals Sets Q3 Earnings Call, Plans Major Healthcare Conference Tour | SPRY Stock News - StockTitan
William Blair Has Positive Forecast for SPRY FY2024 Earnings - MarketBeat
(SPRY) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Raymond James & Associates Invests $2.97 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $24.00 Consensus Target Price from Brokerages - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of “Buy” by Analysts - Defense World
Here's Why 'Trend' Investors Would Love Betting on ARS Pharmaceuticals, Inc. (SPRY) - MSN
Allspring Global Investments Holdings LLC Invests $2.58 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals shares a new treatment for allergic reactions - KATV
New Data on Needle Free Epinephrine Spray Presented at ACAAI 2024 - Patient Care Online
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data - GlobeNewswire
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - StockTitan
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5%Here's Why - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Hits New 12-Month HighHere's Why - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Trading 4.3% HigherTime to Buy? - MarketBeat
ARS Pharmaceuticals, Inc. (SPRY) is on the Move, Here's Why the Trend Could be Sustainable - MSN
ARS Pharmaceuticals' chief medical officer sells $1.49 million in stock By Investing.com - Investing.com Australia
Here's Why We're Not At All Concerned With ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation - Yahoo Finance
Ars Pharmaceuticals CFO Kathleen Scott sells $200,000 in stock - Investing.com
Ars Pharmaceuticals CFO Kathleen Scott sells $200,000 in stock By Investing.com - Investing.com Canada
Ars Pharmaceuticals CEO sells $1.49 million in stock By Investing.com - Investing.com South Africa
Ars Pharmaceuticals CEO sells $1.49 million in stock - Investing.com India
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):